Explainable AI in Healthcare, What Actually Earns Clinical Trust

Explanation is not evidence

The most common demand made of clinical AI is that it explain itself. The assumption underneath that demand is that an explanation builds trust, exposes bias, and makes a model safe to act on. That assumption is half right and half dangerous. A model that shows its reasoning is not the same as a model that has been shown to work. For clinical teams deciding what to act on, and for the administrators and health-tech leaders deciding what to buy, the gap between explanation and evidence is the distinction that matters most.

Why explainability became the demand

Modern diagnostic and prognostic models are mostly deep neural networks whose internal logic is not legible to the people using them. A 2026 systematic review in Health Science Reports, covering 70 studies published between 2017 and 2025, found the field has converged on a small set of explanation techniques, namely SHAP, LIME, Grad-CAM, and attention maps, used across oncology, cardiology, and clinical decision support (Shiddik, 2026). Clinicians, reasonably, want a reason before they act. Interview research finds practitioners gravitate to feature-importance scores precisely because they are fast to read, while also cautioning that this surface simplicity can be deceptive (Röber and colleagues, 2025).

Evidence grade: strong on what the field does, since this rests on a systematic review. The claim that explanations build trust is weaker and more contested, as the rest of this piece shows.

Where current methods genuinely help

Explanation has real uses, and they are mostly upstream of the bedside.

During development, saliency maps and feature attributions are useful for catching a model that has learned the wrong thing. The textbook failures, a skin model keying on a ruler in dermatology photos or a chest imaging model reading a scanner token rather than the lung, were found by inspecting what the model attended to. Explanations also support bias auditing and debugging, and they can give a clinician a starting point to verify against the chart rather than a verdict to accept. These are oversight and quality-assurance functions. They are not a substitute for the clinician's own judgment, and they are not proof the model is correct.

Where they mislead

The harder finding is that post-hoc explanations approximate the model, they do not reveal it. A widely cited 2021 viewpoint in The Lancet Digital Health by Ghassemi, Oakden-Rayner, and Beam argued that current explainability methods are a false hope for patient-level decisions, because post-hoc explainers produce plausible but unreliable narratives that can foster overconfidence and confirmation bias (Ghassemi and colleagues, 2021). The 2026 systematic review reinforces the structural problem: there is still no standardized metric for interpretability, so two methods can disagree with no neutral way to adjudicate, and most methods have not been validated in real clinical settings.

Evidence grade: the Lancet piece is an expert viewpoint rather than a trial, so treat it as argument, not data. But its core technical claim, that post-hoc methods estimate rather than expose a model's reasoning, is well established and not seriously disputed. The risk it points to is practical. A confident-looking explanation can make a wrong recommendation feel safe.

What regulators actually ask for

This is where buyers most often misread the room. Regulators are not asking for prettier heatmaps. They are asking for validation and disclosure across the product lifecycle.

The FDA's January 2025 draft guidance for AI-enabled device software functions takes a total product lifecycle approach. It asks submissions to cover the model description, data lineage, performance tied to the specific claims made, bias analysis, the human-AI workflow, and post-market monitoring, and it frames explanations as something that should be clinically relevant and appropriate to the intended user rather than impressive in the abstract (FDA, AI-enabled medical devices).

In Europe, the AI Act classifies medical AI as high-risk and phases in transparency and human-oversight obligations through 2026 and 2027, with general purpose model obligations already live since August 2025 (Regulation (EU) 2024/1689). The Medical Device Regulation itself does not mandate explainable AI as a named requirement, but auditors expect manufacturers to demonstrate they understand how their model reaches a conclusion. The regulatory center of gravity, in other words, sits closer to prove it works and disclose its limits than to show a saliency map.

The counterargument, and where it lands

The false-hope framing is not the last word. A 2022 response in the same journal argued that abandoning explainability in favor of validation alone is specious, since explanation and validation answer different questions (Lancet Digital Health, 2022). The reasonable synthesis is that validation tells you whether to trust a model in general, while a good explanation can help a clinician decide whether to trust it on this patient, in this moment. You need both, and you should not let one stand in for the other.

A short checklist for clinical and procurement teams

When evaluating a system, ask less about how it explains and more about what stands behind it.

• Validation. Has it been tested prospectively, in your setting or one like it, against the outcome you care about, not only retrospective accuracy? The State of Clinical AI 2026 report from the ARISE network, a Stanford and Harvard led synthesis, stresses exactly this gap between controlled performance and real-world behavior (Stanford Medicine, 2026).
• Data transparency. Do you know the training population, and where it does not match your patients?
• Limits and failure modes. Does the vendor disclose where the model is unreliable, or only where it performs well?
• Monitoring. Is there drift detection, and a defined escalation path for when the model and the clinician disagree?
• Explanations. Are they clinically meaningful and checkable against the record, or simply convincing to look at?

A vendor who answers the first four well, and is honest about the fifth, is more trustworthy than one selling a beautiful explanation interface.

The takeaway

Explainability is worth having, but it is the smallest part of trust. The intelligence layer healthcare actually needs does not just make a model legible. It makes the model auditable: validated against outcomes, transparent about its data and its limits, and monitored while it runs. Legibility without that is comfort, not safety. We treat explanation as one input to justified trust, never as a replacement for the evidence that earns it.